Navigation Links
Long-term Oral Steroid Therapy Decreases Lymphoma Risk in Rheumatoid Arthritis

According to a study, two years or more of oral steroid treatment decreases the risk of rheumatoid arthritis (RA) related lymphoma.

Furthermore, these effects were found regardless of when in the course of the disease the steroids were first administered. However, these beneficial effects were not observed if the steroids were taken for less than a two-year period.

The pros and cons of corticosteroid treatment in rheumatoid arthritis have been a subject of much debate and long term steroid treatment is often limited as a result of concerns about various side effects, Study author Dr Eva Baecklund of Uppsala University Hospital, Sweden, said.

What our data show is a new aspect of steroid treatment. Patients with severe rheumatoid arthritis are at increased risk for malignant lymphomas (cancer in the immune system), but long term steroid treatment may decrease this risk, Baecklund added.

In individuals treated with steroids for over two years, the risk of rheumatoid arthritis-associated lymphomas was significantly reduced (relative risk 0.4; 0.2-0.7), whilst less than two years of steroids yielded no such reduced risk (relative risk 0.9; 0.5-1.5).

The most pronounced protective steroidal effect was observed in the diffuse large B-cell lymphoma subtype - the type of lymphoma most commonly associated with RA 1,2,3 with an odds ratio of 0.7 (0.4-1.0).

The study involved 378 patients with rheumatoid arthritis-associated lymphoma identified from the Swedish Hospital Register and the Cancer Register compared with 378 individually matched RA controls, i.e. patients with RA but without lymphoma.

Using data on steroid treatment type and duration along with inflammatory load collected from cases and controls, information on lymphoma type (where observed) was also collected. The lymphoma tissues were obtained from the pathology laboratories and were reclassified according to the most recent lymphoma classification, the World Health Organization classification.

Interestingly, researchers also compiled information on the duration of RA at initiation of steroid treatment. In this study there was no correlation observed between protective function and length of RA at onset of steroidal treatment.

The protective effect was identical in those starting steroid treatment the first five years after onset of RA and in those starting later (relative risk 0.6; 0.3-0.9). Steroid treatment outcome was not associated with the presence of the Epstein-Barr virus in the lymphomas.

These results build on those of a previously published study that reported that orally prescribed and intra-articular (administered within the joint or joint cavity) steroids protect the individual from the development of malignant (actively cancerous) lymphomas in a dose responsive manner.


'"/>




Related medicine news :

1. Long-term use of calcium supplements to prevent colon cancer
2. Long-term Care Should Be A Planned Affair
3. Long-term Ibuprofen Therapy After Brain Injury Deteriorate Cognitive Abilities
4. Global AIDS Conference Calls for Long-term Strategies
5. Long-term Use of Stomach Drugs may Weaken Bones
6. Asthma Sufferers Favor Quick Relief Over Long-term Control
7. Long-term Marijuana Smoking Leads to Respiratory Complaints
8. Tamoxifen Yields Long-term Reduction in Breast Cancer Risk
9. Angioplasty Reduces Long-term Cardiac Risk in Heart Patients With silent Ischemia
10. Functional Foods Must Be Monitored to Assess Their Long-term Safety and Effectiveness
11. Long-term Use of Herceptin Does Not Increase Heart Failure in Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... , ... February 23, 2017 , ... ... of Justice jointly issued a letter to withdraw previous guidance issued ... their gender identity. The guidance issued in May 2016 by the Obama Administration ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... 23, 2017 , ... ERT, a global data and technology ... Research, a leading clinical development service provider, has selected ERT’s Trial Oversight suite ... in part to an array of circumstances including the use of multiple data ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... of around 1.8% over the next decade to reach approximately $12.8 billion ... estimates and forecasts for all the given segments on global as well ...
Breaking Medicine Technology: